FDA Warning Letters
This article was originally published in The Silver Sheet
Executive Summary
WARNING LETTERS: Baxter citations follow FDA inspections at seven facilities; Philips failed to establish procedures for complaint handling and Medical Device Reporting, FDA says
You may also be interested in...
New tactic: Warning letters to health care providers
On Oct. 27, FDA sent warning letters to 17 ambulatory surgical centers that perform laser-assisted in situ keratomileusis (LASIK) procedures, citing the facilities for failure to develop, maintain and implement written Medical Device Reporting (MDR) procedures. (See "1Warning Letters") CDRH has also stepped up communications with health care facilities and professional societies to clarify the agency's requirements for MDR reporting. CDRH Office of Compliance Director Tim Ulatowski says it's "vitally important" that user facilities, and not just device manufacturers, comply with MDR regulations. Under the regulation, hospitals and other user facilities must submit a report to both FDA and the manufacturer when a device may have caused or contributed to a death. When it may have caused or contributed to a serious injury, the facility generally only needs to tell the manufacturer. "If the manufacturers aren't getting the reports and FDA is not getting the reports from user facilities when necessary, then the whole system breaks down, or is at least in jeopardy," Ulatowski says. "We need to be receiving these reports so we can properly assess in a post-market period how these devices that are involved in LASIK procedures are performing.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.